Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 94.1 USD
Weaknesses
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
EXACT SCIENCES CORPORATION-8.19%20 568
GUARDANT HEALTH, INC.4.96%13 585
BGI GENOMICS CO., LTD.1.61%8 244
INVITAE CORPORATION-18.34%6 714
ADAPTIVE BIOTECHNOLOGIES CO..-28.58%5 879
IOVANCE BIOTHERAPEUTICS, IN..-30.26%4 756
-
CAREDX, INC-10.93%3 344
VERACYTE, INC.-2.92%3 183
SEEGENE INC--.--%2 824
Q-LINEA AB (PUBL)-20.88%425
BIOVICA INTERNATIONAL AB (P..-29.30%120
EPIGENOMICS AG-36.03%15
More Results
Financials
Sales 2021 1 747 M - 1 263 M
Net income 2021 -586 M - -423 M
Net Debt 2021 776 M - 561 M
P/E ratio 2021 -35,5x
Yield 2021 -
Capitalization 20 568 M 20 568 M 14 874 M
EV / Sales 2021 12,2x
EV / Sales 2022 10,0x
Nbr of Employees 4 900
Free-Float 93,4%
Upcoming event on EXACT SCIENCES CORPORATION
03/09/21
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes